# Micron Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/micron-biomedical

- Industry: Biotechnology
- Headquarters: Atlanta, US
- Website: www.micronbiomedical.com
- Total disclosed funding: $32M
- Latest round: Series A (Dec 11, 2024)
- Investors on record: 5

## About

Micron Biomedical, Inc. is a US-based company specializing in innovative healthcare solutions, particularly in needle-free vaccine and medicine delivery through proprietary dissolvable microarray technology, enhancing accessibility to essential pharmaceuticals.Founded in 2014, Micron Biomedical, Inc. operates out of Atlanta, US, focusing on needle-free delivery systems for vaccines and medicines. The company has completed 8 deals with its most recent funding being a Grant of USD 2.000 mn from the Biomedical Advanced Research and Development Authority on January 14, 2025. The total amount raised by the company is USD 15.000 mn. The founders, Devin McAllister, Mark Prausnitz, and Sebastien Henry, have experience in healthcare innovation, and the current CEO is Steven Damon.Micron Biomedical specializes in innovative healthcare solutions, primarily focusing on needle-free vaccine and medicine delivery through its proprietary dissolvable microarray technology. This core product enables painless self-administration of therapeutics, enhancing access to essential pharmaceuticals for both children and adults. Micron's technology addresses critical challenges in traditional vaccine delivery methods, such as the need for cold chain logistics, potentially improving accessibility in remote or underserved areas. The company’s products are suitable for various settings, including home use and field applications, targeting a global market with specific outreach to developing countries facing vaccine hesitancy and logistical barriers.Micron Biomedical's revenue model involves partnerships, direct sales to healthcare providers, and collaborations with public health organizations. The company generates income by supplying its needle-free delivery systems to healthcare entities that facilitate vaccine distribution. Although specific pricing for its products is not disclosed, Micron is positioned to capitalize on the increasing demand for user-friendly vaccine solutions that minimize healthcare professional intervention.In January 2025, Micron Biomedical, Inc. received USD 2 million in grant funding from the Biomedical Advanced Research and Development Authority to advance its research and development for a needle-free vaccine. The company aims to launch new products within this domain while exploring opportunities to expand into additional markets, particularly in regions with limited healthcare infrastructure. The funding will be utilized to support these initiatives and enhance the company's position in the healthcare sector.

## Funding rounds

- Series A, Dec 11, 2024, $15M — J2 Ventures, Global Health Investment Corporation
- Series A, Apr 4, 2023, $3M — J2 Ventures
- Series A, Nov 22, 2022, $14M — GRA Venture Fund, LTS Lohmann Therapie-Systeme AG, Global Health Investment Advisors

## Investors

- GRA Venture Fund (https://capitalatlas.ai/funds/gra-venture-fund) — Series A
- LTS Lohmann Therapie-Systeme AG — Series A
- Global Health Investment Advisors — Series A
- J2 Ventures (https://capitalatlas.ai/funds/j2-ventures) — Series A
- Global Health Investment Corporation (https://capitalatlas.ai/funds/global-health-investment-corporation) — Series A